We are live on ! Find out more
PRVL

Prevail Therapeutics Inc. Common Stock
PRVL

Delisted

PRVL was delisted on the 21st of January, 2021.

Back to rankings

0 hedge funds and large institutions have $0 invested in Prevail Therapeutics Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 92 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 93 → 0 (-93)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

100% less capital invested

Capital invested by funds: $648M → $0 (-$648M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 92

Holders
–
Holders Change
-93
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
92
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$319M
2
Citadel Advisors
Citadel Advisors
Florida
-$55.8M
3
BlackRock
BlackRock
New York
-$28.4M
4
BC
Boxer Capital
California
-$25.9M
5
AAM
Alpine Associates Management
Florida
-$19.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
51
Morgan Stanley
New York
– -$506K -21,936 Closed
California State Teachers Retirement System (CalSTRS)
52
California State Teachers Retirement System (CalSTRS)
California
– -$502K -21,767 Closed
Dimensional Fund Advisors
53
Dimensional Fund Advisors
Texas
– -$485K -21,020 Closed
State of Wisconsin Investment Board
54
State of Wisconsin Investment Board
Wisconsin
– -$445K -19,300 Closed
WC
55
Wexford Capital
Florida
– -$437K -18,963 Closed
Two Sigma Advisers
56
Two Sigma Advisers
New York
– -$420K -18,200 Closed
PCM
57
Pentwater Capital Management
Florida
– -$408K -17,694 Closed
First Trust Advisors
58
First Trust Advisors
Illinois
– -$382K -16,571 Closed
Two Sigma Investments
59
Two Sigma Investments
New York
– -$371K -16,082 Closed
William Blair & Company
60
William Blair & Company
Illinois
– -$357K -15,455 Closed
RhumbLine Advisers
61
RhumbLine Advisers
Massachusetts
– -$352K -15,258 Closed
New York State Common Retirement Fund
62
New York State Common Retirement Fund
New York
– -$348K -15,100 Closed
Walleye Capital
63
Walleye Capital
New York
– -$347 -15,025 Closed
DAM
64
Deltec Asset Management
New York
– -$346K -15,000 Closed
MTCM
65
Mint Tower Capital Management
Netherlands
– -$3K -15,000 Closed
Deutsche Bank
66
Deutsche Bank
Germany
– -$248K -10,768 Closed
Manulife (Manufacturers Life Insurance)
67
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$235K -10,186 Closed
HA
68
Havens Advisors
New York
– -$231K -10,000 Closed
JF
69
Jump Financial
Illinois
– -$215K -9,309 Closed
AIG
70
American International Group
New York
– -$192 -8,301 Closed
SO
71
STRS Ohio
Ohio
– -$186K -8,100 Closed
JP Morgan Chase
72
JP Morgan Chase
New York
– -$175K -7,560 Closed
MIM
73
MetLife Investment Management
New Jersey
– -$155K -6,723 Closed
CAC
74
Cowen and Company
New York
– -$127K -5,523 Closed
Barclays
75
Barclays
United Kingdom
– -$110K -4,778 Closed
1 2
3
4

PRVL Hedge Fund Activity: Q1 2021 in Review

0 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics Inc. Common Stock (PRVL) for Q1 2021, worth a combined $0 — down 100% from $648M a quarter earlier.

Sellers outnumbered buyers: 92 funds closed out of PRVL and 0 opened new positions — a net loss of 92 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was OrbiMed, exiting entirely with an estimated $319M sold.

  • 0 institutional investors held Prevail Therapeutics Inc. Common Stock (PRVL) as of Q1 2021, down from 93 in Q4 2020.
  • Funds reported $0 of Prevail Therapeutics Inc. Common Stock stock for Q1 2021, down 100% quarter-over-quarter.
  • 0 funds opened new Prevail Therapeutics Inc. Common Stock positions in Q1 2021 and 92 closed out, a net change of -92 holders.
  • The largest Prevail Therapeutics Inc. Common Stock seller in Q1 2021 was OrbiMed, an estimated $319M sold.

Based on aggregated 13F filings for Q1 2021.